Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin for Unfavorable Bleeding in Contraceptive Implant Users
NCT04205929Phase 4Completed
- Sponsor
- Oregon Health & Science University
- Start
- Apr 2020
- Primary completion
- Nov 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in breakthrough bleeding comparing Curcumin group with Placebo group (2 arms). Primary endpoint: Total Number of Days Without Bleeding or Spotting at 30 days. Started Apr 2020; status: completed.
02
Drugs
curcumin
03
Conditions
breakthrough bleeding
Beyond the preview
Go deeper on NCT04205929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205929.